Compare Amphastar Pharmaceuticals Inc (AMPH) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Tenet Healthcare Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Tenet Healthcare Corporation trades at $260.39 (market cap $20.93B). The key difference: Tenet Healthcare Corporation is far larger — about 24.2× Amphastar Pharmaceuticals Inc's market cap, and Tenet Healthcare Corporation is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | THC | |
|---|---|---|
Market Cap | $863.95M | $20.93B |
Sector | Health | Health |
52-Week High | $30.81 | $262.63 |
52-Week Low | $16.87 | $161.37 |
Enterprise Value | $1.26B | $32.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Tenet Healthcare (THC) trades at $262.13, up 2.14% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with Q2 2026 EPS beating estimates at $6.12 versus $4.26 expected, while valuation metrics remain attractive with P/E of 10.05 and EV/EBITDA of 5.74. Recent institutional buying and positive earnings revisions support the upward trend.
Outlook remains positive with consensus price target of $281.44 offering 7.4% upside potential. Key risks include healthcare policy headwinds and competitive pressures, but strong ambulatory growth and expense management provide fundamental support. The stock presents a compelling value-growth combination for investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
